25 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Feb 2029
Next term end
12
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2033 · High confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends Apr 2032 · High confidence
Extracellular Matrix from Pluripotent Cells
US 10,702,554
Cited by 29 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2033.
Methods and Composition for Treating Neural Degeneration
US 8,945,919
The most cited patent in this portfolio, cited by 44 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2030.
Methods and Compositions for Modulating Peripheral Immune Function
US 9,655,927
Cited by 22 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Methods and Compositions for Stimulation of Cell Proliferation and Provision of Biologically Active Mixtures of FGF2 Isoforms (US 10,363,285) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Extracellular Matrix from Pluripotent Cells (US 10,471,102) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jul 28, 2027The maintenance fee for Methods and Compositions for Modulating Peripheral Immune Function (US 10,543,234) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Methods and Compositions for Modulating Peripheral Immune Function (US 11,903,972) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 2 fees due Oct 2 to 26, 2027 · next Oct 2
- 1 fee due Nov 3, 2027The maintenance fee for Methods and Compositions for Treatment of Retinal Degeneration (US 9,326,999) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 12 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods and Compositions for Modulating Peripheral Immune Function | 4 in force | to Apr 2035 |
| Induction Medium and Methods for Stem Cell Culture and Therapy | 3 in force | to Nov 2034 |
| Methods and Compositions for Modulating Angiogenesis and Vasculogenesis | 3 in force | to Feb 2034 |
| Extracellular Matrix from Pluripotent Cells | 3 in force | to Sep 2033 |
| Cell Delivery System and Methods of Operation Thereof | 2 in force | to Sep 2039 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,471,102 | Extracellular Matrix from Pluripotent Cells In force · High confidence | In force | High confidence | |
| US 10,653,724 | Extracellular Matrix from Pluripotent Cells In force · High confidence | In force | High confidence | |
| US 8,945,919 | Methods and Composition for Treating Neural Degeneration In force · High confidence | In force | High confidence | |
| US 9,655,927 | Methods and Compositions for Modulating Peripheral Immune Function In force · High confidence | In force | High confidence | |
| US 10,543,234 | Methods and Compositions for Modulating Peripheral Immune Function In force · High confidence | In force | High confidence | |
| US RE46,382 | Methods and Compositions for Modulating Peripheral Immune Function In force · Low confidence | In force | Low confidence | |
| US 10,245,286 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis In force · Medium confidence | In force | Medium confidence | |
| US 9,326,999 | Methods and Compositions for Treatment of Retinal Degeneration In force · High confidence | In force | High confidence | |
| US 9,855,299 | Methods and Compositions for Treatment of Retinal Degeneration In force · High confidence | In force | High confidence | |
| US 10,702,554 | Extracellular Matrix from Pluripotent Cells In force · High confidence | In force | High confidence |
Also on record, not counted in the 25: 2 patents in force now held by others · 8 patents ended · 13 applications pending · 18 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.